Randomized controlled trial on the effectiveness of two drug regimens in the treatment of cervicitis with HR-HPV infection
Objective To investigate the practical effect of recombinant human interferon α2b vaginal effervescent tablets and policresulen solution combined with Baofukang suppository in the treatment of cervicitis with high-risk human papilloma virus(HR-HPV)infection.Methods A total of 80 patients with cervicitis with HR-HPV infection admitted in Jiangyin Lingang Hospital from January 2022 to September 2023 were randomly divided into group A and group B,with 40 cases in each group.The group A was treated with recombinant human interferon α2b vaginal effervescent tablets,and the group B was treated with policresulen solution combined with Baofukang suppository.The therapeutic effects of the two groups were compared.Results The total effective rate of cervicitis treatment in the group B was higher than that in the group A(P＜0.05).After treatment,the HR-HPV load of the group B was lower than that of the group A(P＜0.05);the negative conversion rate of HR-HPV in the group B was higher than that in the group A(P＜0.05).After treatment,the levels of interleukin-1β(IL-1β),interleukin-4(IL-4)and interleukin-6(IL-6)in the group B were lower than those of the group A(P＜0.05).After treatment,CD4+ in the group B was higher than that in the group A,and CD8+ was lower than that in the group A(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Compared with recombinant human interferon α2b vaginal effervescent tablets,policresulen solution combined with Baofukang suppository is more effective in the treatment of cervicitis with HR-HPV infection,and more safe and reliable.
cervicitishigh-risk human papilloma viruspolicresulen solutionBaofukang suppository
万方数据
维普
